ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Hangzhou Sumgen Biotech Co., Ltd. clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 12 studies whose lead sponsor is Hangzhou Sumgen Biotech Co., Ltd. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 17, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

Compare Hangzhou Sumgen Biotech with Qilu Pharmaceutical and Sino Biopharmaceutical →

Pipeline: 4 programs

Each counted once: 4 with a study Hangzhou Sumgen Biotech Co., Ltd. leads registered in the last two years.

  • Phase 2
  • Phase 3

The 1 phase-3 program — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Hangzhou Sumgen Biotech Co., Ltd.’s own registered studies; Hangzhou Sumgen Biotech Co., Ltd.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Hangzhou Sumgen Biotech Co., Ltd.’s studies test, most open studies first — 1 drug with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Coming up

6 of Hangzhou Sumgen Biotech Co., Ltd.’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. 1F
  5. 2M
  6. A
  7. 1M
  8. J
  9. J
  10. A
  11. 2S
  12. O
  13. N

Add all 6 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 19, 2026.

All 12 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now758%Recruiting 6 · Not yet recruiting 1
  • Under way, not recruiting18%
  • Completed325%
  • Stopped early18%

Phase

  • Phase 18
  • Phase 25
  • Phase 31

Where

  • China11
  • United States1

Over the years

  1. 21
  2. 22
  3. 523
  4. 24
  5. 25
  6. 526

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Hangzhou Sumgen Biotech Co., Ltd.

  • Hangzhou Sumgen Biotech Co., Ltd.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    12 studies

Studies

Recruiting first, then most recently updated. Showing 12 of 12.